Background
==========

Chemotherapy is still the current standard treatment for hematological malignancy and febrile neutropenia is a common complication of chemotherapy in most patients \[[@B1]\]. If fever persists 72-96 hours after treatment with broad-spectrum antibacterial antibiotics during neutropenia, invasive fungal infection may be suspected and treated empirically with antifungal agents \[[@B1]-[@B3]\]. However, since the culture methods are insensitive and radiologic findings are nonspecific, the diagnosis of invasive fungal infection remains a challenge \[[@B4]\]. An international consensus on the diagnosis of opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants was established by the Invasive Fungal Infections Cooperative Group of the European Organization for Research and Treatment of Cancer (EORTC) and the Mycoses Study Group of the National Institute of Allergy and Infectious Diseases (MSG-NIAID) \[[@B5],[@B6]\]. Delay in the treatment of invasive fungal infection during neutropenia causes high mortality in patients with transplants and hematological malignancy \[[@B4],[@B5],[@B7]\]. The uncertainty in disease diagnosis results in under- or over-treatment of invasive fungal infection. Despite the availability of several new antifungal agents, including triazoles and echinocandins, the effectiveness of antifungal therapy remains uncertain and the effectiveness of neutrophil recovery may not be sufficient if the recovering neutrophils are dysfunctional \[[@B8]\].

Invasive fungal sinusitis (IFS) is a rare disease largely attributable to *Aspergillus*and *Mucor*in patients with stem cell transplants and hematological disease \[[@B9]\]. Though the mortality of IFS in immunocompromised patients ranges from 50% to 80% \[[@B7],[@B9],[@B10]\], early physical findings are non-specific and ambiguous (i.e., nasal obstruction, purulent discharge, and epistaxis). Water\'s view plain radiographs do not distinguish invasive fungal sinusitis from chronic allergic sinusitis. Bony erosion and tissue destruction is often found only in the advanced stage by computed tomography \[[@B11],[@B12]\]. Recent introduction of serial *Aspergillus*galactomannan antigen test may provide early evidence of IFS. In this study, clinical characteristics were retrospectively reviewed and their correlation with outcome was evaluated to identify prognostic factors in patients with hematological disorders and IFS.

Methods
=======

Patients
--------

National Taiwan University Hospital is a 2200-bed teaching hospital that provides both primary and tertiary care in metropolitan Taipei. More than 600 admissions annually comprise adult patients with hematological malignancies for in-patient chemotherapy. Lymphoma, acute myeloid leukemia and myeloma were the three most common hematological diagnoses \[[@B13]\].

The search terms \"sinusitis\" and \"sinonasal infection\" were used to identify reports in the discharge summary database of all patients admitted to the Department of Internal Medicine between January 1995 and December 2009. Patients with hematopoietic stem cell transplants, hematological disease (including severe aplastic anemia, pure red cell aplasia, and hematological malignancy), and sinusitis diagnosed during their hospital stay were enrolled in this study. Patients with hematological disorders and chronic non-invasive sinusitis admitted in the same period of time cohort were enrolled as controls. Demographic features, hematological disease status, underlying medical diseases, chemotherapy regimen before diagnosis of fungal sinusitis, evidence (clinical, microbiological, pathological, and radiological) showing fungal sinusitis, antifungal therapy, and outcome were collected and analyzed retrospectively. This research conformed to the Helsinki Declaration and local legislation, and approved by the local ethics committee.

Diagnosis of Sinusitis
----------------------

During the study period, patients with hematological malignancy developed sinusitis were routinely to take sinus X-ray and otolaryngist was consulted for focal evaluation and tissue culture. CT and MRI sinus study, surgical biopsy and debridement were performed according to clinicians\' decision.

Diagnosis, Prophylaxis and Treatment of invasive fungal sinusitis
-----------------------------------------------------------------

Physicians clinically diagnosed IFS in all these patients according to EORTC/MSG-NIAID consensus criteria in 2008 \[[@B5],[@B6]\]. The host factors included prolonged neutropenia (\< 500 neutrophils/mm^3^for \> 10 days) temporally related to the onset of fungal disease, receipt of an allogeneic stem cell transplant, prolonged use of corticosteroids, immunosuppressive agents, or nucleoside analogues during the past 90 days. The clinical criteria included imaging showing sinusitis plus at least one of the following three signs: acute localized pain, nasal ulcer with black eschar, extension from the paranasal sinus across the bony barrier. The microbiological criteria included culture or isolation of fungus from surgical material or sinus aspirate samples, and detection of *Aspergillus*galactomannan antigens in serum. In our institution, an optical density (OD) index of 0.5 or higher is considered positive for aspergillus galactomannan test.

No routine anti-fungal prophylaxis was prescribed in hematological patients receiving standard chemotherapy. Fluconazole was used as antifungal prophylactic agent in the recipients of stem cell transplantation. Timing and choice of pre-emptive anti-fungal therapy was based on clinical judgment according to the presence of any of the following high risk factors: local symptoms and signs of sinusitis, elevated serum *Aspergillus*galactomannan antigen, or abnormal CT imaging. The maintenance dose of each antifungal agent is as following: amphotericin B 1-1.5 mg/kg/day, amphotericin B liposomal 3-5 mg/kg/day, capsofungin acetate 50 mg/day, and voriconazole 400 mg/day.

Proven, probable, and possible invasive fungal sinusitis
--------------------------------------------------------

Proven, probable, and possible IFS were defined mainly according to the EORTC/MSG-NIAID criteria \[[@B5],[@B6]\]. Proven IFS was defined by the presence of fungi associated tissue damage on histopathologic examination of a biopsy specimen; or positive culture result, consistent with infection, from a sample obtained aseptically from a clinically or radiologically abnormal site. Probable IFS was defined by the presence of at least one host factor criterion, one microbiological criterion, and one clinical criterion. Possible IFS was defined by the presence of at least one host factor criterion and one clinical criterion.

Survival and Mortality
----------------------

The survival is defined from diagnosis of invasive fungal sinusitis to patients died. Attributable mortality to invasive fungal sinusitis is defined if patient died within 6 weeks, and there were no other attributable cause of death.

Statistics
----------

Comparisons were made using the chi-square test. Predictors of survival were identified using a Cox regression model. Factors which p level is below 0.2 in the univariate analysis were selected for multivariate Cox regression analysis. All statistical analyses were performed using SPSS 13.0 for Windows (SPSS, Chicago, IL, USA). A p value less than 0.05 was considered statistically significant.

Results
=======

Clinical characteristics of patients with IFS
---------------------------------------------

The diagnosis of invasive fungal sinusitis was made in 46 patients with hematological disorders, and 64 patients with hematological disorders and chronic non-invasive sinusitis admitted in the same period of time cohort were enrolled as controls. There was no outbreak of invasive fungal sinusitis detected in this study. The overall incidence of IFS is 1.77 per 1000 patients. The incidence and trend of IFS in adult hematological patients was shown in Table [1](#T1){ref-type="table"}. There were trends of decreasing incidence and mortality during the study period, although these did not attain statistically significance (p = 0.199 and 0.223).

###### 

Comparison of three different periods of incidence and mortality of patients with hematological disorders and invasive fungal sinusitis (IFS) by χ^2^trend analysis (p = 0.199).

                                Year                    
  ----------------------------- ------- ------- ------- -------
  Case number                   568     674     1355    
  Patient number of IFS         13      11      22      
  Incidence of IFS              2.29%   1.63%   1.62%   0.199
  Patient number of mortality   6       6       7       
  Mortality rate of IFS         46.2%   54.5%   31.8%   0.223

IFS was proven in 25 patients (54%), probable in 5 patients (11%), and possible in 16 patients (35%). Their clinical characteristics are shown in Table [2](#T2){ref-type="table"}. Compared with chronic non-specific sinusitis, IFS was more common in patients with disease subtype of acute myeloid leukemia (AML) than in patients with other types of hematological malignancy (p \< 0.001) and more common in patients with absolute neutrophil count less than 500/mm^3^for ≥10 days. The occurrence of IFS was not affected by underlying diabetes mellitus, hematological disease status, chemotherapy intensity, and allogeneic stem cell transplantation.

###### 

Clinical characteristics of patients with invasive fungal sinusitis.

  --------------------------------------------------------------------------------------------------------------
                                          Sinusitis        EORTC/MSG-NIAID IFS                        
  --------------------------------- ----- ----------- ---- --------------------- ---- --- ------ ---- ----------
  Age                                                                                                 

   \< 60 years                      86    34          52   0.48                  19   5   10     52   0.25

   ≥ 60 years                       24    12          12                         6    0   6      12   

  Gender                                                                                              

   Male                             66    27          39   0.85                  15   3   9      39   0.99

   Female                           44    19          25                         10   2   7      25   

  Hematological diagnosis                                  \< 0.001                                   0.004

   Acute myeloid leukemia           56    33          23                         16   4   13     23   

   Acute lymphoblastic leukemia     16    6           10                         6    0   0      10   

   Lymphoma/myeloma                 20    0           20                         0    0   0      20   

   SAA/MDS                          9     4           5                          2    0   2      5    

   Others\*                         9     3           6                          1    1   1      6    

  Disease status                                           0.24                                       0.38

   Fresh diagnosis/remission        44    15          29                         10   1   4      29   

   Refractory/relapsed              66    31          35                         15   4   12     35   

  Underlying diabetes mellitus                             0.45                                       0.68

   Yes                              7     4           3                          2    1   1      3    

   No                               103   42          61                         22   5   15     61   

  Chemotherapy intensity\*\*                               0.21                                       0.045

   Supportive treatment             34    11          23                         3    4   4      23   

   Low dose chemotherapy            13    8           5                          3    1   4      5    

   Standard dose chemotherapy       47    22          25                         16   0   6      25   

   High dose chemotherapy           16    5           11                         3    0   2      11   

  Absolute neutrophil count                                \< 0.001                                   \< 0.001

   \< 500 mm^3^\< 10 days           55    7           48                         2    1   4      48   

   \< 500 mm^3^≥ 10 days            55    39          16                         23   4   12     16   

  Allogeneic transplantation                               0.07                                       0.013

   Yes                              24    6           18                         2    3   1      18   

   No                               86    40          46                         23   2   15     46   

  FESS debridement                                         0.001                                      \< 0.001

   Yes                              18    14          4                          12   0   2      4    

   No                               92    36          56                         20   1   15     56   

  Pre-emptive antifungal agent                             \< 0.001                                   \< 0.001

  Amphotericin B/ambisome                 28          12                         14   4   10     12   

  Caspofungin                             0           1                          0    0   0      1    

  Voriconazole                            2           0                          2    0   0      0    

  Amphotericin B and caspofungin          4           0                          3    0   1      0    

  Amphotericin B and voriconazole         9           1                          6    0   3      1    

  Outcome (6 weeks survival)                               0.001                                      0.001

   Death                            27    19          8                          7    3   9\     8    
                                                                                          1110        

   Alive                            83    27          56                         18   2   7      56   
  --------------------------------------------------------------------------------------------------------------

Abbreviation: IFS, invasive fungal sinusitis; SAA, severe aplastic anemia; MDS, myelodysplastic syndrome, FESS: functional endoscopic sinus surgery.

\*Others including: chronic myeloid leukemia (2), chronic lymphocytic leukemia (3), T-large granular lymphocyte leukemia (1), myelofibrosis (2), pure red cell aplasia status post transplantation (1)

\*\*High dose chemotherapy includes high dose cytarabine chemotherapy and conditioning therapy before myeloablative transplantation.

Microbiological spectrum
------------------------

Among the 25 patients with proven invasive fungal sinusitis, fifteen patients had positive biopsy showed hyphae with Giemsa stain or PAS stain, and 14 patients showed positive fungal cultures. The fungal isolates from 25 patients with proven invasive fungal sinusitis included: *Aspergillus flavus*(12), *Aspergillus fumigatus*(2), *Aspergillus vesicolor*(1), *Aspergillus sybowii*(1), unidentified Aspergillus species (1), *Mucor*(4), *Phaeohyphomyces*(1), *Fusarium*(1), *Penicillium*(1), and unidentified fungal species (1).

*Aspergillus*galactomannan antigen test
---------------------------------------

Sixteen patients during 2005 to 2009 had serial follow-up of *Aspergillus*galactomannan antigen. The mean value (+/- SD) of *Aspergillus*galactomannan antigen test is 2.32 (+/- 1.86). The mean value (standard deviation) of Aspergillus galactomannan antigen in the seven patients with positive results was 2.32 (1.86), compared with those with negative results 0.13 (0.07). The p value (0.048) is below 0.05. *Aspergillus*galactomannan antigen was not elevated in three patients with mucormycosis sinusitis. *Aspergillus*galactomannan antigen was elevated in seven of eleven patients with *aspergillus*sinusitis. One patient with *phaeohyphomycosis*-related sinusitis and one patient with sinusitis caused by *Fusarium*and *Penicillium marneffei*also showed elevated *aspergillus*galactomannan antigen. The sensitivity of serum galactomannan antigen testing was 64% and the specificity was 60% for the detection of invasive *aspergillus*sinusitis. (Table [3](#T3){ref-type="table"})

###### 

Aspergillus galactomannan test for detect invasive aspergillosis

  ------------------------------------------------------------------------------------------------------
                                   Patients with\           Patients with non-Aspergillus sinusitis\*\
                                   Aspergillus sinusitis\   (n = 5)
                                   (n = 11)                 
  -------------------------------- ------------------------ --------------------------------------------
  Aspergillus galactomannan test                            

   Positive test                   7                        2

   Negative test                   4                        3
  ------------------------------------------------------------------------------------------------------

\*Patients with non-Aspergillus sinusitis: mucormycosis, (3 patients); phaeohyphomycosis, (1); fusariosis/penicilliosis (1)

Radiological manifestations
---------------------------

Sinus imaging by computed tomography (CT) or magnetic resonance (MRI) were performed in 44 (96%) of patients with IFS and 37 (59%) of 63 patients with chronic non-specific sinusitis. Evidence of extra-sinus tissue involvement and/or bony destruction were detected in 15 (33%) of patients with IFS. In addition, brain abscess complicating IFS was found in two patients and cavernous sinus thrombosis in one patient.

Treatment and outcome
---------------------

Pre-emptive antifungal treatment was given in 43 (94%) of 46 patients with IFS. Fourteen of sixty-four patients with non-IFS received pre-emptive antifungal therapy initially, and these agents were discontinued after excluding the diagnosis of IFS. The overall mortality rate of patients with IFS was 41% (Table [2](#T2){ref-type="table"}). The attributable mortality of patients with AML was also much higher than non-AML patients. All the patients died rapidly due to IFS (median survival, 15 days; 25^th^and 75^th^percentile, 10 and 34 days, respectively). Six-week survival was not significantly different between patients who had received antifungal combination therapy (amphotericin B plus capsofungin and amphotericin B plus voriconazole vs amphotericin B) compared to those who had received monotherapy (p = 0.74). All four patients with *mucormycoses*had received high dose antifungal therapy and aggressive surgical debridement, but three died within 6 weeks. Twelve patients with proven invasive fungal sinusitis and two patients with possible invasive fungal sinusitis underwent functional endoscopic sinus surgery for debridement. The median interval between diagnosis and surgical debridement is 11.5 days (range 1-38 days). Nineteen of 46 patients (41%) with IFS and 8 of 64 patients (13%) with non-invasive sinusitis died within 6 weeks after diagnosis of sinusitis. The 6-week mortality rate was significantly higher in patients with IFS than those with non-invasive sinusitis (p = 0.001). Univariate analysis of 6-week outcomes in patients with hematological disorders and invasive fungal sinusitis is summarized in Table [4](#T4){ref-type="table"}. The acute myeloid leukemia disease subtype (p = 0.044) and refractory disease status were associated with worse outcomes (p = 0.05). The intensity of chemotherapy and allogeneic stem cell transplantation were not independent prognostic factors of invasive fungal infection in this study. The median interval between neutropenia and diagnosis of IFS was not significantly different between non-survivors and survivors (median 19 days vs 21 days, *p*= 0.677). Multivariate Cox regression analysis revealed functional endoscopic sinus surgery for debridement as the only independent prognostic factor for survival (p = 0.047).

###### 

Univariate analysis outcome in patients with hematological disorders.

                                     IFS (n = 46)   *P*   Odds Ratio   95%CI   
  ---------------------------------- -------------- ----- ------------ ------- -------------
  Age                                                     0.51                 
   ≥ 60 years                        6              6                          
   \< 60 years                       21             13                         
  Gender                                                  0.55                 
   Male                              17             10                         
   Female                            10             9                          
  Hematological diseases                                  0.04         5.84    1.02-30.56
   AML                               16             17                         
   Non-AML\*                         11             2                          
  Disease status                                          0.05         4.27    1.003-18.15
   Fresh diagnosis/remission         12             3                          
   Relapse/refractory                15             16                         
  Underlying diabetes mellitus                            \> 0.99              
   Yes                               2              2                          
   No                                25             17                         
  Chemotherapy intensity                                  0.25                 
   Supportive care                   5              6                          
   Low dose chemotherapy             3              5                          
   Standard dose chemotherapy        16             6                          
   High dose chemotherapy            3              2                          
  Absolute neutrophil count                               0.68                 
   \< 500 mm^3^\< 10 days            5              2                          
   \< 500 mm^3^≥10 days              22             17                         
  Allogeneic transplantation                              0.68                 
   Yes                               3              3                          
   No                                24             16                         
  FESS debridement                                        0.10         0.27    0.064-1.17
   Yes                               11             3                          
   No                                16             16                         
  Fungus type                                             0.21                 
   Aspergillosis                     12             5                          
   Mucormycosis                      2              2                          
   Others\*\*                        2              2                          
   Unknown                           10             12                         
  Invasive image pattern\*\*\*                            0.34                 
   Yes                               7              8                          
   No                                20             11                         
  Pre-emptive antifungal agent                            0.29                 
   Amphotericin B/ambisome           15             13                         
   Caspofungin                       0              0                          
   Voriconazole                      2              0                          
   Amphotericin B and caspofungin    1              3                          
   Amphotericin B and voriconazole   7              4                          

Abbreviation: AML, acute myeloid leukemia; FESS: functional endoscopic sinus surgery.

\*Non -AML: including acute lymphoblastic leukemia 6 cases, severe aplastic anemia/myelodysplastic syndrome, 2 cases, other: CLL, 2 cases, CML 1 case

\*\*. Others: Phaeohyphomycosis, *Fusarium*mycosis, *Penicillium*mycosis, and unidentified mycosis

\*\*\*. Invasive image pattern indicates brain abscess, invasion of tissue.

Discussion
==========

In this large retrospective study, we estimated IFS occurred in 1.77% of hospitalized patients with hematological disorders. IFS caused significantly higher mortality in AML patients with prolonged neutropenia (\> 10 days). We identified surgical debridement is an independent factor associated with good outcome.

IFS developed more frequently in patients with AML, myelodysplastic syndrome, and aplastic anemia, but not at all in patients with lymphoma/myeloma. In the literature review, most patients with lymphoma who developed IFS are recipients of myeloablative allogeneic stem cell transplants \[[@B14]-[@B18]\]. Compared with other subtypes of hematological malignancy, patients with AML had significantly higher risk of IFS. The risk of developing IFS in AML relates to neutropenia (p \< 0.001) and less to the intensity of chemotherapy regimens. The mortality of patients with AML was also much greater than non-AML patients.

Prolonged neutropenia in patients with myeloid malignancies may contribute to underlying disease, intensity and dosage of chemotherapy, colony-stimulating factor, and concurrent medication. Invasive mold infection often occurs when a large burden of spores from an environmental source is deposited on mucosal membranes lacking an effective phagocytic host defense \[[@B19]\]. Using cytokine growth factors to decrease the period of chemotherapy-associated neutropenia and using laminar air flow rooms for protection against IFS \[[@B20]\] may reduce the risk of IFS after allogeneic stem cell transplantation \[[@B21]\]. In this study, we found a lower incidence and mortality of IFS in 2005-2009 than in 1994-1999.

The clinical mycological spectrum of IFS is limited in patients with stem cell transplants and hematological disease \[[@B14]-[@B18]\]. *Aspergillus*and *Mucor*are the main mold found in biopsy, however, the prevalence is highly variable in different geographic regions \[[@B14]-[@B18],[@B22],[@B23]\]. In our study, *Aspergillus flavus*(44%) was the most common isolate. *Aspergillus flavus*, with its unique ability to survive at higher temperatures, is the predominant pathogen in countries, including most of the Middle East, Africa, and Southeast Asia \[[@B24],[@B25]\]. Rare IFS in Asia and Africa were reported, the clinical response varies differently with fungal subtypes, and further epidemiology study should be investigated. *Mucormycosis*is an emerging cause of IFS with a rapid fatal course in patients with hematological disorders \[[@B26],[@B27]\]. In our study, all four patients with *mucormycoses*had received high dose antifungal therapy and aggressive surgical debridement, but three died within 6 weeks (mortality, 75%). Effective treatment for *Mucormycosis*should be investigated.

The symptoms and signs of paranasal sinusitis (such as nasal discharge, stuffiness, epistaxis, periorbital swelling, and maxillary tenderness) are nonspecific for IFS. Symptoms and signs such as nose ulceration, eschar of the nasal mucosa, black necrotic lesions, and perforation of the hard palate are more specific, but these findings are present only at an advanced stage. The use of CT and MRI in the diagnosis of invasive fungal sinusitis has been reported \[[@B12]\]. Diagnostic radiological evidence of invasive fungal sinusitis includes erosion of sinus walls, extension of infection to neighboring structures, and extensive skull base destruction. However, most patients do not have classic findings in the early phase of invasive fungal sinusitis. Earlier diagnosis by using serial Aspergillus galactomannan antigen test in the modern medical era to detect IFS, may lead to early introduce anti-fungal agent and surgical debridement, and potentially decreased morbidity and mortality in high risk patients.

There are some limitations in this study. First, this is a retrospective time cohort study in a single university institution in Taiwan. Therefore, information of laboratory results, such as *Aspergillus*galactomannan antigen test, might be limited. Second, surgical approach of sinusitis were performed according to clinicians\' decision, thus, the etiology of control patients were not available. Third, as IFS is not a common disease in patients with heamatological disorder, the case numbers is limited.

In conclusion, outcome of IFS is usually very poor \[[@B11],[@B28]\]. In this study, functional endoscopic sinus surgery for debridement was the only indicator of better prognosis in multivariate analysis. This result confirms previous findings indicating that sinus surgery improves outcome \[[@B28],[@B29]\]. Aggressive surgical debridement combined with antifungal therapy, should be emphasized in leukemic patients in spite of their prolonged neutropenia and bleeding tendencies. Whether the intensity of chemotherapy and allogeneic stem cell transplantation were the independent prognosis of invasive fungal infection need further investigation.
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